|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The INK4a-ARF locus encodes two tumor suppressor proteins involved in cell-cycle regulation, p16INK4a and p14ARF, whose functions are inactivated in many human cancers.
|
11232644 |
2001 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In malignant glioma specimens, homozygous p16 gene deletions were significantly more common in high-grade tumors than in low-grade gliomas.
|
9049826 |
1997 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The Ink4a/Arf (CDKN2a) locus encodes two proteins that regulate two of the most important tumor suppressor pathways represented by p53 and Rb.
|
15846097 |
2005 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Allelic deletions within this chromosomal region most often include the tumour suppressor gene p16.
|
12690309 |
2003 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
HDs were also noted for known tumor suppressor genes (TSG), including CDKN2A, CDKN2B, SMAD4, and GALR1, and identified PDE4D and MGC48628 as potentially novel TSGs.
|
18519675 |
2008 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Both cell lines showed homozygous deletion of the representative tumor suppressor p16 and p15 genes, but no p53 gene alteration.
|
10359144 |
1999 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Germline mutations in the tumour suppressor gene CDKN2A occur in 5-20% of familial melanoma cases.
|
24935963 |
2014 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Sequencing of each exon of both tumour suppressor genes revealed p16INK4A mutation only in 3 out of 11 BL, but 1 of them also affected the p14ARF gene.
|
16158958 |
2005 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Homozygous deletions of p16 were identified in 5 of 23 (22%) primary tumors; no mutations or rearrangements were found in these specimens.
|
7923195 |
1994 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
By comparing the sixteen analyzed loci in lung AD tissues and AdjNL and non-tumor (NL) tissues, we found that, among the six genes identified with hypermethylation, the HOXA11, CDKN2A-EX2 and EYA4 genes showed highly promising DNA hypermethylation diagnostic markers in the lung AD tissues.
|
28380439 |
2017 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Although the ABL kinase inhibitor imatinib mesylate (Gleevec) provides highly effective treatment for BCR-ABL-positive chronic myelogenous leukemia, it has proven far less efficacious in the treatment of BCR-ABL-positive acute lymphoblastic leukemias (ALLs), many of which sustain deletions of the INK4A-ARF (CDKN2A) tumor suppressor locus.
|
16618932 |
2006 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We identified a miR-877-3p binding site on the promoter site of tumor suppressor gene p16 which alters frequently in bladder cancer.
|
27429046 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The apparent lack of other mutations in p16 and p15 in the tumors with loss of heterozygosity leaves open the possibility of an unidentified gene in this region that may function as a tumor suppressor.
|
9816033 |
1995 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Losses on 9p21.3 harboring the CDKN2A/B locus were significantly more common in primary tumors from sequential and discrepant (nonequal) pairs.
|
24706357 |
2014 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Four (44%) p16 negative samples were hypermethylated at the p16(INK4a) promoter region; the other p16 negative tumors that showed no hypermethylation revealed BMI-1 staining.
|
15892997 |
2005 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The p16(INK4A) gene and Rb gene are key tumor suppressor genes in a cell cycle regulatory pathway that is commonly inactivated in various cancers.
|
17052587 |
2006 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The highest specificity was seen for the p16 gene, and this was associated with a odds ratio of six for methylation in the tumour when this gene was methylated in sputum.
|
17406356 |
2007 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Indeed, known phenotypes associated with germ-line p16 mutations and an apparent correlation between the deletion span and tumor spectrum in the two families suggest a new model of cancer pathogenesis based on the inactivation of contiguous tumor suppressor genes, an alternative to the established pleiotropic effects of single-gene disruption.
|
9622062 |
1998 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The INK4a/ADP ribosylation factor (ARF) locus encodes two tumor suppressor genes: p16INK4a and p14ARF. p16INK4a has been shown to be of major significance in cholangiocarcinoma.
|
12738733 |
2003 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Beside CDKN2A, other genes (e.g., CDKN2B, and ARF/p14(ARF), long considered distinct from CDKN2A) on this locus are often deleted or mutated in a large number of tumors including glioma, bladder cancer, and lung cancer.
|
18406873 |
2008 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutation, H3F3A mutation, CDKN2A loss) in this tumor group.
|
30298540 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The total mutational burden was similar between human papillomavirus (HPV)-negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors.
|
29747488 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The CDKN2A/ARF locus encompasses overlapping tumor suppressor genes p16(INK4A) and p14(ARF), which are frequently co-deleted in human malignant mesothelioma (MM).
|
21526190 |
2011 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Assessment of CMM case subjects from CDKN2A families with and without pancreatic cancer revealed no statistically significant differences in median age at diagnosis (P =.80) or in tumor number (P =.24).
|
10861313 |
2000 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To confirm the significance of p16 gene deletion in tumour biology of RMS, a temperature-sensitive p16 mutant (E119G) gene was retrovirally transfected into the human RMS cell line RD, which has homozygous gene deletion of p16 gene.
|
10098732 |
1999 |